A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

ConclusionSingle-agent AR-42 is safe and well tolerated. Further studies may consider AR-42 in a larger cohort of patients with NF2 or in combination with other agents in advanced solid tumors.Trial registrationNCT01129193, registered 5/24/2010.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research